AU2008316051A1 - Pharmaceutical product comprising yeast - Google Patents

Pharmaceutical product comprising yeast Download PDF

Info

Publication number
AU2008316051A1
AU2008316051A1 AU2008316051A AU2008316051A AU2008316051A1 AU 2008316051 A1 AU2008316051 A1 AU 2008316051A1 AU 2008316051 A AU2008316051 A AU 2008316051A AU 2008316051 A AU2008316051 A AU 2008316051A AU 2008316051 A1 AU2008316051 A1 AU 2008316051A1
Authority
AU
Australia
Prior art keywords
pharmaceutical product
yeast
pharmaceutical
active
ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008316051A
Other languages
English (en)
Inventor
Bodo Asmussen
Gregor Garbacz
Stefan Nagel
Mahmoud A. Omer-Adam
Christiane Schiller
Werner Weitschies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40299087&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008316051(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of AU2008316051A1 publication Critical patent/AU2008316051A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2008316051A 2007-09-01 2008-08-21 Pharmaceutical product comprising yeast Abandoned AU2008316051A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007041588A DE102007041588A1 (de) 2007-09-01 2007-09-01 Arzneimittel mit Hefe
DE102007041588.7 2007-09-01
PCT/EP2008/006897 WO2009052888A2 (de) 2007-09-01 2008-08-21 Arzneimittel mit hefe

Publications (1)

Publication Number Publication Date
AU2008316051A1 true AU2008316051A1 (en) 2009-04-30

Family

ID=40299087

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008316051A Abandoned AU2008316051A1 (en) 2007-09-01 2008-08-21 Pharmaceutical product comprising yeast

Country Status (14)

Country Link
US (1) US20120027856A1 (cg-RX-API-DMAC7.html)
EP (1) EP2180885B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010536903A (cg-RX-API-DMAC7.html)
KR (1) KR101259673B1 (cg-RX-API-DMAC7.html)
CN (1) CN101795676B (cg-RX-API-DMAC7.html)
AU (1) AU2008316051A1 (cg-RX-API-DMAC7.html)
CA (1) CA2698327C (cg-RX-API-DMAC7.html)
DE (1) DE102007041588A1 (cg-RX-API-DMAC7.html)
ES (1) ES2456267T3 (cg-RX-API-DMAC7.html)
MX (1) MX2010002167A (cg-RX-API-DMAC7.html)
NZ (1) NZ584233A (cg-RX-API-DMAC7.html)
RU (1) RU2452473C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009052888A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201000853B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009027938A1 (de) * 2009-07-22 2011-01-27 Universität Greifswald Orales therapeutisches System und seine Verwendung
EP2839377A4 (en) * 2012-04-20 2015-12-02 Enmotus Inc STORAGE SYSTEM WITH DATA MANAGEMENT MECHANISM AND METHOD FOR OPERATION THEREOF
WO2015190456A1 (ja) * 2014-06-10 2015-12-17 ライオン株式会社 清酒酵母を含有する錠剤
US11291683B2 (en) * 2016-04-01 2022-04-05 Access Business Group International Llc Bilayer tablets of B vitamins and process for preparing the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675174A (en) * 1985-08-16 1987-06-23 Alza Corporation Veterinary dispenser delivering beneficial agent by gas power generated in situ
EP0737473A1 (en) 1989-10-02 1996-10-16 Cima Labs, Inc. Effervescent dosage form
WO2000076478A1 (en) * 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
DE10120092B4 (de) * 2001-04-25 2008-03-20 Lts Lohmann Therapie-Systeme Ag Magensaftresistente Vorrichtung zur Freisetzung von mukoadhäsiven Wirkstoffträgern und Verfahren zur Herstellung der magensaftresistenten Vorrichtung
GB0114069D0 (en) * 2001-06-08 2001-08-01 Smithkline Beecham Plc Composition
WO2002102415A1 (en) * 2001-06-18 2002-12-27 Blue Cross Laboratories Limited Gastric floating system
WO2003000112A2 (en) 2001-06-20 2003-01-03 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of ribonuclease l in diagnosis of cancer
DE10224607B4 (de) * 2002-06-04 2008-03-13 Lts Lohmann Therapie-Systeme Ag Filmförmige, zerfallsfähige Zubereitungen zur Wirkstofffreisetzung und Verfahren zu deren Herstellung
CA2501345A1 (en) * 2002-10-11 2004-04-22 Depomed Development, Ltd. Gastro-retentive levodopa delivery form
US6835397B2 (en) * 2002-12-23 2004-12-28 Balchem Corporation Controlled release encapsulated bioactive substances
US20060003003A1 (en) 2004-06-28 2006-01-05 Bakker Johan A Oral sustained release formulation of tedisamil with gastric retention properties
DE102004042139B4 (de) 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
US20060093592A1 (en) * 2004-10-04 2006-05-04 Nutracea Synbiotics
US7799328B2 (en) * 2004-12-23 2010-09-21 Biocodex Method for treating weight loss in patients suffering from inflammatory bowel diseases
WO2009008726A1 (en) * 2007-07-12 2009-01-15 Dsm Ip Assets B.V. Nitrate reduction by a probiotic in the presence of a heme

Also Published As

Publication number Publication date
DE102007041588A1 (de) 2009-03-05
ES2456267T3 (es) 2014-04-21
MX2010002167A (es) 2010-04-29
CN101795676A (zh) 2010-08-04
KR101259673B1 (ko) 2013-05-06
WO2009052888A2 (de) 2009-04-30
WO2009052888A3 (de) 2009-10-15
NZ584233A (en) 2012-02-24
ZA201000853B (en) 2010-10-27
RU2452473C2 (ru) 2012-06-10
RU2010109523A (ru) 2011-10-20
JP2010536903A (ja) 2010-12-02
US20120027856A1 (en) 2012-02-02
CN101795676B (zh) 2012-11-28
CA2698327A1 (en) 2009-04-30
CA2698327C (en) 2013-04-30
KR20100059880A (ko) 2010-06-04
EP2180885B1 (de) 2014-01-29
EP2180885A2 (de) 2010-05-05

Similar Documents

Publication Publication Date Title
AU2002338897B2 (en) Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt
US20120034274A1 (en) Pharmaceutical composition comprising one or more fumaric acid esters
US20080286343A1 (en) Solid form
AU2002338897A1 (en) Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt
US20150246043A1 (en) Oral dosage forms for modified release comprising ruxolitinib
WO2004103372A1 (en) Pharmaceutical compositions of varenicline
WO2009047799A1 (en) High dose solid unit oral pharmaceutical dosage form of mycophenolate sodium and process for making same
CN101695575A (zh) 含有他汀类降脂药物、双胍类降糖药物和烟酸的药物组合物
CA2698327C (en) Pharmaceutical product comprising yeast
US9555003B2 (en) Oral solid formulation of compound anti-tubercular drug and preparation method thereof
CN102920707A (zh) 一种复方抗结核制剂的制备工艺
CN111494328B (zh) 一种含阿卡波糖和达格列净的渗透泵片及其制备方法
CN104224739A (zh) 一种以恩替卡韦为主药成分的口服固体组合物
CN117679382A (zh) 吗替麦考酚酯胃黏附渗透泵控释片及其制备方法
KR20080110876A (ko) 박동성 방출을 위한 경구용 제약 코팅 조성물
CN101869567A (zh) 含有双胍类降糖药物和沙坦类降压药物的药物组合物及其用途
CN101695492A (zh) 含有他汀类降脂药物、磺脲类降糖药物和烟酸的药物组合物
CN117679383A (zh) 吗替麦考酚酯胃漂浮控释片及其制备方法
CN101869572A (zh) 含有双胍类降糖药物和普利类降压药物的组合物及其用途
CN101011368A (zh) 曲克芦丁的缓释制剂
HK1189504B (en) Oral solid preparation of compound antituberculosis drug and preparation method thereof
HK1067861B (en) Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt
HK1189504A (en) Oral solid preparation of compound antituberculosis drug and preparation method thereof

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application